Inhibition of c-Src/p38 MAPK pathway ameliorates renal tubular epithelial cells apoptosis in db/db mice

Haijiang Wu1, Yonghong Shi1, Xinna Deng2

  • 1Department of Pathology, Hebei Medical University, Shijiazhuang, China; Key Laboratory of Kidney Diseases of Hebei Province, Shijiazhufang, China.

Insights

Inhibition of the c-Src/p38 MAPK pathway reduces renal tubular epithelial cell apoptosis in diabetic kidney disease. This finding offers a potential therapeutic target for diabetic nephropathy complications.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Cell Biology

Background:

  • Diabetic nephropathy (DN) involves renal tubular epithelial cell (RTEC) apoptosis, contributing to kidney failure.
  • The precise mechanisms linking hyperglycemia to RTEC apoptosis remain unclear.

Purpose of the Study:

  • To investigate the role of the c-Src/p38 MAPK pathway in RTEC apoptosis.
  • To determine if inhibiting this pathway affects DN progression.

Main Methods:

  • Diabetic db/db mice were treated with a c-Src inhibitor (PP2).
  • Human RTEC (HK-2 cells) were exposed to high glucose (HG) in vitro.
  • Western blotting, TUNEL assay, and flow cytometry were used to assess apoptosis and pathway activation.

Main Results:

  • PP2 treatment reduced kidney weight, urinary volume, and markers of kidney damage in diabetic mice.
  • PP2 inhibited c-Src and p38 MAPK activation, decreasing the Bax/Bcl-2 ratio and cleaved caspase-3.
  • In vitro, HG induced RTEC apoptosis via c-Src/p38 MAPK activation, which was reversed by PP2 and a p38 MAPK inhibitor (SB203580).

Conclusions:

  • Inhibition of c-Src reduces RTEC apoptosis in diabetic kidneys, partly by suppressing p38 MAPK activation.
  • The c-Src/p38 MAPK pathway is a key mediator of hyperglycemia-induced RTEC apoptosis in DN.
  • Targeting this pathway may offer a therapeutic strategy for diabetic kidney disease.

Related Concept Videos